Abstract 5353
Background
9-ING-41 is a first-in-class, intravenously (IV) administered, small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity in a broad spectrum of malignancies, both as a single agent and in combination with cytotoxic agents. GSK-3β is a serine/threonine kinase important in tumor progression and modulation of oncogenes, cell cycle regulators and mediators of epithelial-mesenchymal transition. Aberrant overexpression of GSK-3β is associated with advanced stage and aggressive tumor growth as well as chemotherapy resistance.
Trial design
This Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41 as a single agent and in combination with cytotoxic agents, in patients with refractory cancers. Treatment consists of twice-weekly IV infusion of 9-ING-41 as a single agent (21-day-cycle) or combined with chemotherapeutic agents including gemcitabine, doxorubicin, lomustine, carboplatin, nab-paclitaxel, or paclitaxel. Study parts 1 and 2 will evaluate the safety and tolerability, describe any dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) and the recommended Phase 2 study dose (RP2D) for 9-ING-41 as monotherapy (Part 1) and in combination with chemotherapies (Part 2). Part 3 (Simon 2-Stage Phase 2 at the RP2D) will assess clinical benefit in patients with relapsed or refractory malignancies treated with 9-ING-41-based combinations at the RP2D established in Part 2. Safety will be assessed by recording and monitoring adverse events (CTCAE). For solid tumors, response will be defined by response evaluation criteria in solid tumors (RECIST) 1.1 criteria in the evaluable lesion(s). For lymphoma, response will be assessed per the International Working Group Response Criteria. For CNS tumors, response will be followed by the RANO and the MacDonald criteria. The study is opening in 25 sites globally and will accrue approximately 250 patients.
Clinical trial identification
NCT03678883.
Editorial acknowledgement
Legal entity responsible for the study
Actuate Therapeutics Inc.
Funding
Actuate Therapeutics Inc.
Disclosure
B. Carneiro: Research grant / Funding (institution): Actuate Therapeutics Inc; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer. L. Cavalcante: Research grant / Funding (institution): Actuate Therapeutics Inc. P. Munster: Research grant / Funding (institution): Actuate Therapeutics Inc. F. Giles: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Actuate Therapeutics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract